Customize your JAMA Network experience by selecting one or more topics from the list below.
Aisen PS, Schafer KA, Grundman M, et al. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. JAMA. 2003;289(21):2819–2826. doi:10.1001/jama.289.21.2819
Author Affiliations: Department of Neurology, Georgetown University Medical Center, Washington, DC (Dr Aisen); Department of Neurosciences, University of California, San Diego (Ms Schafer and Drs Grundman, Jin, and Thal); Suncoast Gerontology Center, University of South Florida College of Medicine, Tampa (Dr Pfeiffer); Department of Psychiatry (Dr Sano), Mount Sinai School of Medicine, Mount Sinai Medical Center (Dr Davis), New York, NY; Department of Neurology, School of Medicine, Indiana University, Indianapolis (Dr Farlow); Departments of Family and Preventive Medicine and Neurosciences, University of California, San Diego (Dr Thomas).
Context Laboratory evidence that inflammatory mechanisms contribute to neuronal
injury in Alzheimer disease (AD), along with epidemiological evidence, suggests
that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence
the course of the disease.
Objective To determine whether treatment with a selective cyclooxygenase (COX)
-2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows
cognitive decline in patients with mild-to-moderate AD.
Design Multicenter, randomized, double-blind, placebo-controlled, parallel
group trial, with 1-year exposure to study medications.
Setting Forty ambulatory treatment centers affiliated with the Alzheimer's Disease
Cooperative Study consortium.
Participants Participants with mild-to-moderate AD (Mini-Mental State Examination
score of 13-26) were recruited from December 1999 to November 2000 using clinic
populations, referrals from community physicians, and local advertising. Stable
use of cholinesterase inhibitors, estrogen, low-dose aspirin, and vitamin
E was allowed. Participants with inflammatory diseases that might respond
to the study medications were excluded. Of 474 participants screened, 351
Interventions Once-daily rofecoxib, 25 mg, or twice-daily naproxen sodium, 220 mg,
Main Outcome Measures The primary outcome measure was the 1-year change in the Alzheimer Disease
Assessment Scale-Cognitive (ADAS-Cog) subscale score. Secondary outcome measures
included the Clinical Dementia Rating scale sum-of-boxes, the Neuropsychiatric
Inventory, the Quality of Life-AD, and the time to attainment of significant
end points (4-point decline from baseline ADAS-Cog score, 1-step worsening
on the global Clinical Dementia Rating scale, 15-point decline on the ADCS
activities of daily living inventory, institutionalization, or death).
Results The 1-year mean (SD) change in ADAS-Cog scores in participants treated
with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not significantly different
from the change in participants treated with placebo (5.7 [8.2]). Results
of secondary analyses showed no consistent benefit of either treatment. Fatigue,
dizziness, and hypertension were more commonly reported in the active drug
groups, and more serious adverse events were found in the active treatment
group than in the placebo group.
Conclusion The results of this study indicate that rofecoxib or low-dose naproxen
does not slow cognitive decline in patients with mild-to-moderate AD.
Create a personal account or sign in to: